Steatotic liver disease

The Lancet, Journal Year: 2024, Volume and Issue: 404(10464), P. 1761 - 1778

Published: Nov. 1, 2024

Language: Английский

---

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(6), P. 930 - 940

Published: July 4, 2024

Language: Английский

---

Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa

Liver International, Journal Year: 2024, Volume and Issue: 44(4), P. 1061 - 1070

Published: Feb. 2, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in general population among patients T2D Middle East North Africa (MENA) region.

Language: Английский

---

Opportunities and challenges following approval of resmetirom for MASH liver disease

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(12), P. 3402 - 3405

Published: April 19, 2024

Language: Английский

---

Liver Cancer in 2021: Global Burden of Disease Study

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease in adults

Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 6, 2025

Language: Английский

---

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 5, 2025

ABSTRACT Objective Primary liver cancer (PLC) is projected to be the third leading cause of mortality in United States 2040. We examine burden PLC States, stratified by sex, state and aetiological risk factors. Methods Data on prevalence, incidence, death disability–adjusted life years (DALYs) were extracted from Global Burden Disease Study 2021. Changes these parameters calculated using Joinpoint regression model. Results There 47,970 cases, 31,450 incident 24,770 deaths 576,920 DALYs States. The highest prevalence (16,980), incidence (12,040), (9840) (213,410) due chronic hepatitis C virus infection. From 2000 2021, incidences increased 141%, 136%. Age–standardised rates (ASIRs) (ASDRs) per 100,000 population for increased, primarily driven alcohol–related disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) metabolic dysfunction–associated steatotic (MASLD) +2.32%; +2.04%). Conclusion has risen past two decades, mainly ALD followed MASLD. These findings offer policymakers an accurate assessment emphasise need targeted factor mitigation, especially regarding alcohol related policy.

Language: Английский

---

Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes patients with MASLD compared general population Sweden. In this population-based cohort study, we identified individuals an ICD-10 code for inpatient or specialized outpatient care using Swedish healthcare registers 2002-2020 (n=13,099) matched them up 10 controls (median 9) age, sex, municipality, calendar year (n=118,884). used Cox regression estimate adjusted hazard ratios (HR) 95% confidence intervals (CI) eleven primary death. 15-year cumulative incidences were calculated while accounting competing risks. total, 1,628 (12.4%) deaths occurred 9,119 (7.7%) during a median follow-up 4.7 (interquartile range [IQR] 2.0-9.2) 5.8 years (IQR 2.7-10.5), respectively. was associated higher all-cause (HR=1.85, 95%CI=1.74-1.96) rates all specific except mental health disorder. The strongest associations observed non-hepatocellular carcinoma (HCC) liver-related (HR=26.9, 95%CI=19.4-37.3) HCC-related (HR=35.0, 95%CI=17.0-72.1). However, highest estimated incidence non-HCC cancer (7.3%) cardiovascular (7.2%). strongly liver- mortality, but absolute risks disease. Mortality increased nearly MASLD, suggesting that earlier multidisciplinary is needed reduce excess mortality. Previous studies either small, restricted relying biopsy identify thus inducing selection bias, mainly data old cohorts. nationwide study diagnosed Sweden between 2002 2020, found doubled than wide causes, indicating may be premature MASLD. estimates our useful clinicians policymakers inform about their prognosis potentially implement clinical public strategies

Language: Английский

---

Interleukin-13 (IL-13)—A Pleiotropic Cytokine Involved in Wound Healing and Fibrosis

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(16), P. 12884 - 12884

Published: Aug. 17, 2023

The liver, as a central metabolic organ, is systemically linked to metabolic–inflammatory diseases. In the pathogenesis of syndrome, inflammatory and interactions between intestine, adipose tissue lead progression hepatic steatosis metabolic-dysfunction-associated steatohepatitis (MASH) consecutive MASH-induced fibrosis. Clinical animal studies revealed that IL-13 might be protective in development MASH through both preservation functions Th2-polarized inflammation liver tissue. contrast, IL-13-associated loss mucosal gut barrier function enhanced fibrosis may contribute MASH. However, there are only few publications on effect diseases possible therapies influence them. this review article, different aspects effects diseases, which partly contradictory, summarized discussed basis recent literature.

Language: Английский

---

Envisioning how to advance the MASH field

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: June 4, 2024

Language: Английский

---